News

Opus Genetics

Clinical 50/100How we got 50/100Source tierUnclassified sourceTier ceiling50/100Independent sourcesnot recordedPublished score50/100Scored at the ceiling for a unclassified source source — it cannot go higher. The number is the source page’s own score, hard-capped at the tier ceiling; corroboration is recorded but cannot lift a score past that cap. Under 40 a claim goes to review instead of publication. Full methodology →
July 28, 2026↗ source

Opus Genetics is advancing clinical programs for inherited retinal diseases (IRDs), specifically targeting LCA5 and BEST1 conditions. The company recently announced FDA alignment on the Phase 3 trial design for OPGx-LCA5, a gene therapy for LCA5-associated retinal disease. Additionally, they provided a timeline update for their OPGx-BEST1 program, reinforcing their commitment to developing genetic treatments for rare eye disorders.

Related peptides

NOTA
We summarize, we don't invent — every detail here traces to a real, linked source, and the badge reflects how trustworthy that source is. Read the original and decide for yourself.